SCHEDULE: Vanguard Group's Cogent Biosciences Stake Drops to Zero

The Vanguard Group reported its beneficial ownership in Cogent Biosciences Inc. has dropped to 0% following an internal corporate realignment.

Summary

• The Vanguard Group's beneficial ownership of Cogent Biosciences Inc. Common Stock is now 0.00 shares, representing 0% of the class.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of Vanguard will report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Cogent Biosciences Inc. as it reflects an internal administrative change in how The Vanguard Group reports its holdings, rather than a strategic divestment based on Cogent's performance or prospects.

Future Outlook

Following an internal realignment on January 12, 2026, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report their beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. These subsidiaries will continue to pursue the same investment strategies.

Management Comments

• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct." Ashley Grim, Head of Global Fund Administration, The Vanguard Group.

Industry Context

StockSavvy.ai notes that this filing primarily reflects an internal administrative and reporting change within The Vanguard Group, a major asset manager. It does not indicate a change in investment strategy or sentiment towards Cogent Biosciences Inc. by Vanguard's underlying funds, but rather a shift in how their collective holdings are reported at the parent company level. This type of realignment is specific to large, complex financial institutions managing numerous funds and accounts.

Stakeholder Impact

• Shareholders of Cogent Biosciences Inc. may observe a change in reported institutional ownership by The Vanguard Group, though the underlying holdings by Vanguard's funds may remain unchanged, simply reported differently.
• Investment professionals tracking institutional ownership will need to consider the disaggregated reporting from Vanguard's subsidiaries for a complete picture of Vanguard's overall exposure to Cogent Biosciences Inc.

Next Steps

• Vanguard's subsidiaries or business divisions will report their beneficial ownership of securities separately on a disaggregated basis.

Key Dates

Keywords

Vanguard Group, Cogent Biosciences, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, Common Stock, Internal Realignment